Lipoprotein(a), often written as Lp(a), is one of the most stubbornly difficult cardiovascular risk factors to treat. Unlike LDL cholesterol, which responds reliably to statins and lifestyle changes, Lp(a) levels are overwhelmingly set by your genes, with roughly 70 to over 90 percent of the variation between people being inherited rather than shaped by diet or habits.1PubMed Central. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association That genetic stubbornness means the usual heart-health playbook falls short, and the most promising approaches are still making their way through clinical trials. But there are options worth understanding right now, and the landscape is shifting fast.
Why Lp(a) Barely Budges With Lifestyle Changes
If you have been told your Lp(a) is high, the first instinct is to do what works for other cholesterol numbers: eat better, exercise more, lose weight. Those steps genuinely help lower LDL cholesterol and triglycerides. For Lp(a), though, the payoff is negligible. Studies consistently show that diet modifications, aerobic exercise, and weight loss have little meaningful impact on circulating Lp(a) levels. The reason is straightforward: your liver produces Lp(a) at a rate dictated almost entirely by the LPA gene you inherited. Environmental factors simply do not override that genetic programming the way they can for other lipoproteins.
That does not mean lifestyle changes are pointless if you have elevated Lp(a). A healthy diet and regular exercise still reduce your overall cardiovascular risk by improving blood pressure, blood sugar, inflammation, and LDL cholesterol. They just will not fix the Lp(a) number itself. Think of it as lowering every other risk factor you can control, because this particular one largely resists your direct efforts.
Statins Do Not Lower Lp(a)
This surprises many people, since statins are the cornerstone of cholesterol management. But a systematic review and meta-analysis looking at statin therapy across patients at risk for cardiovascular disease found that statins do not produce clinically important changes in Lp(a) compared to placebo.2Oxford Academic. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis Some earlier studies even suggested statins could nudge Lp(a) slightly upward, though the effect is small and inconsistent. Either way, if your doctor has prescribed a statin and your Lp(a) remains high, that is expected behavior, not a treatment failure.
The practical takeaway: keep taking your statin if it was prescribed for LDL cholesterol or overall cardiovascular protection, but do not expect it to address Lp(a). They are mechanistically different problems. LDL receptors, which statins upregulate, clear LDL particles efficiently but are not the primary route for clearing Lp(a) from the bloodstream. Your liver makes and removes Lp(a) through pathways that statins barely touch.
PCSK9 Inhibitors Offer a Modest Reduction
The most widely available medications that actually lower Lp(a) right now are PCSK9 inhibitors, injectable drugs originally developed to dramatically cut LDL cholesterol. Two are approved and in clinical use: evolocumab (Repatha) and alirocumab (Praluent). A meta-analysis of randomized controlled trials found that PCSK9 inhibitors reduced Lp(a) levels by an average of about 27 percent.3medRxiv. Impact of PCSK9 Inhibitors on Lipoprotein(a): A Meta-analysis and Meta-regression of Randomized Controlled Trials That same analysis confirmed simultaneous reductions in LDL cholesterol, non-HDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B, along with a slight increase in HDL cholesterol.
A 27 percent drop sounds meaningful, and for some patients it is. But context matters. If your Lp(a) is extremely high, say above 150 nmol/L, a 27 percent reduction still leaves you well above the thresholds associated with increased cardiovascular risk. PCSK9 inhibitors are also not approved specifically for Lp(a) lowering. Doctors prescribe them primarily for LDL cholesterol management, and the Lp(a) reduction is more of a beneficial side effect than the main event. Still, for someone with both elevated LDL and elevated Lp(a), these drugs pull double duty in a way that statins cannot.
The downsides are cost and convenience. PCSK9 inhibitors are self-injected every two to four weeks and remain expensive, though insurance coverage has improved. For patients whose primary concern is Lp(a) rather than LDL, the drugs deliver less bang for the buck than the emerging therapies discussed below.
Niacin and Other Supplements
High-dose niacin (vitamin B3) is one of the few over-the-counter substances that has been shown in older studies to reduce Lp(a) by roughly 20 to 30 percent. For years, it was sometimes recommended for this purpose. The problem is that large cardiovascular outcome trials of niacin, when added to statin therapy, failed to show a reduction in heart attacks or strokes, and the side-effect profile is unpleasant: flushing, itching, liver stress, and worsened blood sugar control. Most major guidelines no longer recommend niacin for cardiovascular risk reduction, and many cardiologists have moved away from prescribing it.
Other supplements marketed for Lp(a), including flaxseed, L-carnitine, coenzyme Q10, and various herbal formulations, lack rigorous evidence of meaningful Lp(a) reduction in well-designed trials. Some show small effects in isolated studies, but nothing consistent or large enough to change cardiovascular outcomes. If you see a supplement advertised as an Lp(a) solution, skepticism is warranted.
RNA-Based Therapies in Development
The most exciting area in Lp(a) management is a new class of drugs designed specifically to slash Lp(a) production at the genetic level. These therapies work by intercepting the messenger RNA your liver uses to manufacture Lp(a), essentially turning down the production line rather than trying to clear the particles after they have already entered your bloodstream.
Several of these drugs are in advanced clinical trials. They fall into a few categories:4SpringerLink / Current Cardiovascular Risk Reports. Current Clinical Trials for Treating Elevated Lipoprotein(a)
- Small interfering RNA (siRNA): Three candidates use this approach, delivered by injection under the skin. siRNA molecules silence the gene’s messenger RNA before it can be translated into the Lp(a) protein. Early-phase trials have reported Lp(a) reductions of 80 percent or more with some of these agents, though outcomes data showing fewer heart attacks and strokes are still pending.
- Antisense oligonucleotides (ASO): A fourth candidate uses a related but distinct RNA-targeting mechanism, also given by subcutaneous injection. Pelacarsen is the most advanced ASO in this space and is being studied in a large cardiovascular outcomes trial.
- Small molecule inhibitor: A fifth agent is an oral pill rather than an injection, which would be a significant convenience advantage if it proves effective and safe.
- CETP inhibitor: A sixth agent, originally studied for LDL cholesterol reduction, has also shown promise for lowering Lp(a) as a secondary benefit.
The siRNA and ASO approaches have generated the most enthusiasm because the magnitude of Lp(a) reduction in phase 2 trials dwarfs anything currently available. Getting Lp(a) down by 80 percent or more would bring many high-risk patients into a range where the added cardiovascular threat from Lp(a) is substantially diminished. The critical unanswered question is whether those dramatic reductions in the blood test actually translate into fewer heart attacks, strokes, and deaths. The outcomes trials are underway, and results are expected within the next few years. If the data are positive, it would mark the first time a therapy specifically targeting Lp(a) has been proven to prevent cardiovascular events.
Lipoprotein Apheresis for Severe Cases
For patients with very high Lp(a) and progressive cardiovascular disease who cannot wait for new drugs, lipoprotein apheresis is a treatment that exists today. It works somewhat like dialysis for cholesterol: your blood is drawn, passed through a filtering system that physically removes Lp(a) and LDL particles, and then returned to your body. Several technical methods exist, including some that separate plasma from red blood cells before filtering and one system that removes lipoproteins directly from whole blood.5PubMed Central. Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review
Apheresis can acutely reduce Lp(a) by 60 to 75 percent in a single session. The catch is that levels rebound within a week or two as the liver keeps producing new Lp(a), so treatments need to be repeated every one to two weeks, indefinitely. Each session takes a few hours, requires specialized equipment at a medical center, and is expensive. Some countries, including Germany, approve and reimburse lipoprotein apheresis for patients with Lp(a) levels above 60 mg/dL and progressive cardiovascular disease.5PubMed Central. Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review In other countries, including the United States, access is more limited and often restricted to patients who have exhausted other options for managing their lipid profiles.
Apheresis is not a practical solution for most people with elevated Lp(a). It is a last-resort intervention for patients at very high cardiovascular risk who are running out of alternatives. If the RNA-based drugs succeed in outcome trials and reach the market, the number of patients who need apheresis will likely shrink considerably.
Managing Overall Cardiovascular Risk When Lp(a) Is High
Because no approved therapy specifically and powerfully lowers Lp(a) yet, the current clinical approach focuses on reducing every other modifiable risk factor as aggressively as possible. If you have elevated Lp(a), your doctor is likely to be more assertive about getting your LDL cholesterol to a lower target, controlling blood pressure tightly, managing blood sugar if you have diabetes or prediabetes, and encouraging you to stop smoking. The logic is compensatory: since you carry a genetic risk factor you cannot yet eliminate, you want to minimize the burden of everything you can control.
This is also where aspirin sometimes enters the conversation, though its role is debated. Some clinicians consider low-dose aspirin for patients with high Lp(a) because the particle has prothrombotic properties, meaning it makes blood clots more likely. But aspirin carries its own bleeding risks, and the net benefit depends on the individual patient’s full risk profile. There is no blanket recommendation to start aspirin solely because Lp(a) is elevated.
Getting Tested in the First Place
One of the biggest barriers to managing Lp(a) is that most people have never had it measured. Standard lipid panels ordered during routine checkups do not include Lp(a). You have to ask for it specifically, or your doctor has to think to order it. The 2019 European Society of Cardiology and European Atherosclerosis Society guidelines made a straightforward recommendation: Lp(a) should be measured at least once in every adult’s lifetime.6PubMed Central. Consensus and guidelines on lipoprotein(a) – Seeing the forest through the trees The American Heart Association has echoed similar guidance, recognizing Lp(a) as a genetically determined, causal risk factor for atherosclerotic cardiovascular disease.1PubMed Central. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
Since Lp(a) levels are genetically fixed and do not change much over your lifetime, a single measurement is usually enough to know where you stand. If the result comes back low, you are unlikely to need repeat testing. If it comes back high, that information reshapes how aggressively you and your doctor should manage your other risk factors. It also puts you on the radar for the new targeted therapies as they become available.
Roughly one in five people has Lp(a) levels high enough to meaningfully increase their cardiovascular risk. Many of them have no idea. If you have a family history of early heart disease or stroke, especially when traditional risk factors like LDL cholesterol do not fully explain it, an Lp(a) test is particularly worth requesting. The test itself is a simple blood draw, and it can reframe your entire prevention strategy.
Why Lp(a) Units Are Confusing
If you do get tested, you may notice that Lp(a) results come in two different units depending on the lab: milligrams per deciliter (mg/dL) or nanomoles per liter (nmol/L). These are not interchangeable with a simple conversion factor the way Fahrenheit and Celsius are, because the molecular weight of Lp(a) varies from person to person due to differences in a region of the particle called apo(a). A result of 50 mg/dL in one person does not correspond to the same nmol/L value as 50 mg/dL in another person.
This has created real confusion in both clinical practice and research. Many guidelines define elevated Lp(a) as above 50 mg/dL or above 125 nmol/L, but these cutoffs are approximations, not exact equivalents. The field is gradually moving toward nmol/L as the preferred unit because it reflects the actual number of Lp(a) particles rather than their mass, which is more biologically meaningful. If your lab report shows mg/dL, you can use it as a rough guide, but the particle-number measurement gives a cleaner picture of risk.
When comparing your results to thresholds discussed in guidelines or studies, check which unit is being used. A result that looks reassuring in one unit might cross the risk threshold in the other, and vice versa. Your doctor should be able to clarify which measurement your lab performed and what it means for your specific situation.
Ethnic Variation in Lp(a) Levels
Lp(a) levels vary substantially across ethnic groups. People of African descent tend to have higher median Lp(a) levels than people of European or East Asian descent. This is driven by differences in the frequency of certain LPA gene variants across populations. The clinical significance of this variation is still being studied: it is not yet clear whether the same Lp(a) threshold confers the same degree of cardiovascular risk across all ethnic groups, or whether population-specific cutoffs might be more appropriate.
This matters practically because most of the large cardiovascular outcome studies that established Lp(a) as a risk factor were conducted predominantly in populations of European ancestry. Applying a single universal threshold to all groups may overestimate risk in some populations and underestimate it in others. Researchers and guideline committees are aware of this gap, and ongoing studies are working to define risk more precisely across diverse populations. In the meantime, if your Lp(a) is elevated, the direction of the risk is clear regardless of your background, even if the exact magnitude is harder to pin down.